for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ジョンソン・エンド・ジョンソン

JNJ.N

現在値

182.29USD

変化

2.63(+1.46%)

出来高

2,722,850

本日のレンジ

179.99

 - 

182.53

52週レンジ

155.72

 - 

186.69

∙ 約20分前の相場を表示しています。

適時開示

Genmab Commences New Arbitration Under License Agreement With Janssen

Genmab A/S <GMAB.CO>::GENMAB COMMENCES NEW ARBITRATION UNDER LICENSE AGREEMENT WITH JANSSEN.GENMAB A/S - WHILE ARBITRATION IS PENDING, GENMAB'S VARIOUS COLLABORATIONS WITH JANSSEN WILL CONTINUE.GENMAB A/S - IN THIS NEW ARBITRATION, GENMAB IS CONSEQUENTLY SEEKING AN AWARD OF $405 MILLION PLUS INTEREST.GENMAB A/S - COMMENCED A NEW ARBITRATION UNDER ITS LICENSE AGREEMENT WITH JANSSEN BIOTECH, INC. (JANSSEN) FOR DARATUMUMAB.GENMAB - SEEKING AWARD FOR DARZALEX FASPRO IN NEW ARBITRATION WITH JANSSEN.GENMAB - SEEKING AWARD FOR DECLARATION THAT IT IS ENTITLED TO A NEW 13-YEAR ROYALTY TERM FROM DATE OF DARZALEX FASPRO'S FIRST COMMERCIAL SALE.

Janssen Presents Initial Results From The Phase 2 Ragnar Study Of Balversa In Patients With Advanced Solid Tumors With FGFR Alterations

June 7 (Reuters) - JANSSEN::JANSSEN PRESENTS INITIAL RESULTS FROM THE PHASE 2 RAGNAR STUDY OF BALVERSA® (ERDAFITINIB) IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FGFR ALTERATIONS.JANSSEN - PRIMARY ANALYSIS FOR ALL PATIENTS TREATED IN THIS RAGNAR COHORT, KNOWN AS BROAD PANEL COHORT, IS ANTICIPATED LATER THIS YEAR.JANSSEN - SAFETY PROFILE OF BALVERSA® OBSERVED IN RAGNAR WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF BALVERSA® IN METASTATIC UROTHELIAL CARCINOMA (MUC).

Yumanity Therapeutics To Merge With Kineta In All-Stock Deal

June 6 (Reuters) - Yumanity Therapeutics Inc <YMTX.O>::YUMANITY THERAPEUTICS ANNOUNCES DEFINITIVE AGREEMENTS FOR TWO STRATEGIC TRANSACTIONS.YUMANITY THERAPEUTICS - TO SELL CLINICAL-STAGE PRODUCT CANDIDATE YTX-7739 & ITS UNPARTNERED DISCOVERY-STAGE NEUROSCIENCE PRODUCT CANDIDATES & TARGETS.YUMANITY - SALE OF YTX-7739 & UNPARTNERED DISCOVERY-STAGE NEUROSCIENCE PRODUCT CANDIDATES AND TARGETS TO JANSSEN PHARMACEUTICA NV FOR $26 MILLION IN CASH.YUMANITY THERAPEUTICS INC - KINETA, INC., A PRIVATE IMMUNO-ONCOLOGY COMPANY, TO MERGE WITH YUMANITY IN AN ALL-STOCK TRANSACTION.YUMANITY - UNDER PROPOSED DEAL WITH JANSSEN, CO PLANS TO DISTRIBUTE ANY REMAINING AVAILABLE CASH PROCEEDS TO STOCKHOLDERS VIA ONE-TIME DIVIDEND.YUMANITY - COMBINED PUBLICLY TRADED CO TO BE RE-NAMED KINETA, INC., THAT WILL FOCUS ON IMMUNO-ONCOLOGY, CONTINUE CO'S ONGOING COLLABORATION WITH MERCK.YUMANITY THERAPEUTICS INC - CURRENT KINETA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 85% OF COMBINED COMPANY.YUMANITY THERAPEUTICS - COMBINED CO EXPECTS TO RAISE CONCURRENT PRIVATE INVESTMENT IN PUBLIC EQUITY LED BY GROWTH & VALUE DEVELOPMENT INC.YUMANITY THERAPEUTICS INC - YUMANITY BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED BOTH DEFINITIVE AGREEMENTS.YUMANITY THERAPEUTICS INC - KINETA BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED DEFINITIVE MERGER AGREEMENT WITH YUMANITY.YUMANITY THERAPEUTICS INC - SHAWN IADONATO, WILL SERVE AS CEO AND CRAIG PHILIPS WILL SERVE AS PRESIDENT OF COMBINED CO.

Janssen Presents Study Results Showing Clinical Efficacy For Tremfya® (Guselkumab) And Long-Term Safety Profile For Stelara® (Ustekinumab) For Patients Living With Inflammatory Bowel Disease At

May 24 (Reuters) - Janssen Pharmaceutical Companies::JANSSEN PRESENTS STUDY RESULTS SHOWING CLINICAL EFFICACY FOR TREMFYA® (GUSELKUMAB) AND LONG-TERM SAFETY PROFILE FOR STELARA® (USTEKINUMAB) FOR PATIENTS LIVING WITH INFLAMMATORY BOWEL DISEASE AT DIGESTIVE DISEASE WEEK® 2022.JANSSEN - OTHER DATA PRESENTED DEMONSTRATE LONG-TERM SAFETY PROFILE OF STELARA® IN BIO-NAÏVE & BIO-FAILURE PATIENTS LIVING WITH INFLAMMATORY BOWEL DISEASE.JANSSEN - DATA SHOW PROPORTIONS OF PATIENTS TREATED WITH TREMFYA WHO ACHIEVED CLINICAL-BIOMARKER RESPONSE RANGED FROM 47.5-66.7% ACROSS DOSE GROUPS.

FDA Grants Breakthrough Device Designation To Anumana's ECG Pulmonary Hypertension Early Detection AI Algorithm

May 24 (Reuters) - Anumana Inc::FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO ANUMANA'S ECG PULMONARY HYPERTENSION EARLY DETECTION AI ALGORITHM.

Johnson & Johnson Appoints Thibaut Mongon As CEO Designate Of Planned New Consumer Health Company

May 11 (Reuters) - JOHNSON & JOHNSON - :JOHNSON & JOHNSON APPOINTS THIBAUT MONGON AS CEO DESIGNATE OF PLANNED NEW CONSUMER HEALTH COMPANY.J&J - PLANNED SEPARATION OF CONSUMER HEALTH BUSINESS EXPECTED TO OCCUR WITHIN 2023.J&J - APPOINTED PAUL RUH AS CFO DESIGNATE OF FUTURE, LISTED NEW CONSUMER HEALTH COMPANY. ((Reuters.Briefs@thomsonreuters.com;)).

FDA Limits Use Of Janssen Covid-19 Vaccine To Certain Individuals

Johnson & Johnson <JNJ.N>::FDA LIMITS USE OF JANSSEN COVID-19 VACCINE TO CERTAIN INDIVIDUALS.FDA - LIMITED AUTHORIZED USE OF JANSSEN COVID-19 VACCINE TO ADULTS FOR WHOM OTHER AUTHORIZED/APPROVED VACCINES ARE NOT ACCESSIBLE/CLINICALLY APPROPRIATE.FDA - DETERMINED THAT KNOWN & POTENTIAL BENEFITS OF JANSSEN COVID-19 VACCINE OUTWEIGH KNOWN, POTENTIAL RISKS FOR INDIVIDUALS 18 YEARS OF AGE & OLDER.FDA - RISK OF THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME IN COMBINATION WITH LOW LEVELS OF BLOOD PLATELETS, WARRANTS LIMITING AUTHORIZED USE JANSSEN VACCINE.FDA - LIMITED AUTHORIZED USE OF JANSSEN COVID-19 VACCINE TO WHO ELECT TO RECEIVE JANSSEN VACCINE BECAUSE THEY WOULD OTHERWISE NOT RECEIVE COVID-19 VACCINE.

Johnson & Johnson Reports Q1 2022 Results

April 19 (Reuters) - Johnson & Johnson <JNJ.N>::REPORTS Q1 2022 RESULTS.Q1 EARNINGS PER SHARE $1.93.Q1 SALES ROSE 5 PERCENT TO $23.4 BILLION.Q1 ADJUSTED EARNINGS PER SHARE $2.67.J&J - SUSPENDING COVID-19 VACCINE SALES GUIDANCE.J&J - COMPANY MAINTAINING 2022 FULL-YEAR GUIDANCE FOR ADJUSTED OPERATIONAL EARNINGS PER SHARE AND BASE BUSINESS OPERATIONAL SALES.J&J - GIVEN GLOBAL SUPPLY SURPLUS AND DEMAND UNCERTAINTY, COMPANY IS SUSPENDING COVID-19 VACCINE SALES GUIDANCE.J&J - QTRLY WORLDWIDE COVID-19 VACCINE SALES $457 MILLION VERSUS $100 MILLION.Q1 EARNINGS PER SHARE VIEW $2.56, REVENUE VIEW $23.61 BILLION -- REFINITIV IBES DATA.J&J SEES FY ESTIMATED REPORTED SALES $94.8 BILLION – $95.8 BILLION.J&J SEES FY ADJUSTED EPS $10.15 - $10.35.FY2022 EARNINGS PER SHARE VIEW $10.51, REVENUE VIEW $99.35 BILLION -- REFINITIV IBES DATA.

Johnson & Johnson Announces Dividend Increase Of 6.6%

April 19 (Reuters) - Johnson & Johnson <JNJ.N>::JOHNSON & JOHNSON ANNOUNCES DIVIDEND INCREASE OF 6.6%.J&J - BOARD OF DIRECTORS HAS DECLARED A 6.6% INCREASE IN QUARTERLY DIVIDEND, FROM $1.06 PER SHARE TO $1.13 PER SHARE.

Vantai Announces Multi-Year Protein Degrader Discovery Collaboration With Janssen

April 13 (Reuters) - Roivant Sciences Ltd <ROIV.O>::VANTAI ANNOUNCES MULTI-YEAR PROTEIN DEGRADER DISCOVERY COLLABORATION WITH JANSSEN.ROIVANT SCIENCES LTD - AGREEMENT WAS FACILITATED BY JOHNSON & JOHNSON INNOVATION.ROIVANT SCIENCES LTD - COLLABORATION WILL INITIALLY FOCUS ON TWO DEGRADER PROGRAMS AS WELL AS A NOVEL E3 LIGASE PLATFORM DEVELOPMENT PROGRAM.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up